Intercell's Ixiaro JE vacc recommended for EU approval
US biotechnology firm Epix Pharmaceuticals has sold the US, Canadian and Australian rights for its blood pool magnetic resonance angiography agent Vasovist (gadofosveset trisodium) to Lantheus Medical Imaging for $28.0 million. Epix will continue to own European and certain other non-US rights for the imaging agent, enabling it to pursue further monetization of the rights. The Massachusetts-based company is trying to restructure its debts to avoid filing for bankruptcy and will pay $10.5 million of the cash proceeds from the sale to its old marketing partner Bayer to cover the German firm's development costs. The two companies terminated their Vasovist accord on February 28.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze